Boehringer Ingelheim Breaks Decade-Long Approval Drought in Idiopathic Pulmonary Fibrosis

By /

In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.

Scroll to Top